Zhang Yimin, Yao Feng, Yao Xiaoli, Yi Changhong, Tan Cheng, Wei Lei, Sun Shengrong
Department of Breast and Thyroid Gland Surgery of Renmin Hospital of Wuhan University, the First College of Clinical Medicine of Wuhan University, Hubei 430060, PR China.
Oncol Rep. 2009 Apr;21(4):1113-21.
This study was undertaken to observe the effects and possible mechanism of CC chemokine ligand 5 (CCL5) on invasion, proliferation and percentage of CD44+/CD24- subpopulation of human breast cancer line MCF-7 and to investigate the correlation of expression levels of CCL5 and its receptors with the progression of breast cancer. We used real-time RT-PCR to detect the expression levels of CCL5 and its receptors CCR5, CCR1 and CCR3 in 36 breast cancer specimens of different TNM stage and their corresponding normal breast tissue. CCL5 expression and invasive ability of four human breast cancer cell lines MCF-7, SK-BR-3, T-47D and MDA-MB-231 were analyzed by real-time RT-PCR and cell invasion assay, respectively. Effects of recombinant human CCL5 (rhCCL5) on cell proliferation and percentage of the CD44+/CD24- subpopulation in MCF-7 cells were analyzed respectively by MTT assay and flow cytometry. We also used cell invasion assay to detect the invasive ability of both CD44+/CD24- and CD44+/CD24+ subpopulations of MCF-7 cells treated with rhCCL5 and/or CCR5 monoclonal antibody. Our results revealed that CCL5 and CCR5 expression were higher in breast cancer tissue than those in their corresponding normal tissue and breast cancer tissue with higher TNM stage contained more CCL5 mRNA. In addition, CCR5 expression and invasive ability of CD44+/CD24- subpopulation were higher than those of CD44+/CD24+ subpopulation of MCF-7 cells. Moreover, treatment of rhCCL5 increased the proportion of CD44+/CD24- cells and the proliferation of MCF-7 cells. Induction of rhCCL5 increased the cell invasive ability of both CD44+/CD24- and CD44+/CD24+ cells, which could be partially antagonized by CCR5 monoclonal antibody. Collectively, our data show that CCL5 increased the proportion of CD44+/CD24- subpopulation and induced invasion and proliferation of MCF-7 cells, and expression of CCL5 and CCR5 in breast cancer tissue was positively correlated with breast cancer progression.
本研究旨在观察CC趋化因子配体5(CCL5)对人乳腺癌细胞系MCF-7侵袭、增殖及CD44+/CD24-亚群比例的影响及其可能机制,并探讨CCL5及其受体表达水平与乳腺癌进展的相关性。我们采用实时逆转录聚合酶链反应(RT-PCR)检测36例不同TNM分期的乳腺癌标本及其相应正常乳腺组织中CCL5及其受体CCR5、CCR1和CCR3的表达水平。分别通过实时RT-PCR和细胞侵袭试验分析四种人乳腺癌细胞系MCF-7、SK-BR-3、T-47D和MDA-MB-231中CCL5的表达及侵袭能力。通过MTT法和流式细胞术分别分析重组人CCL5(rhCCL5)对MCF-7细胞增殖及CD44+/CD24-亚群比例的影响。我们还采用细胞侵袭试验检测经rhCCL5和/或CCR5单克隆抗体处理的MCF-7细胞中CD44+/CD24-和CD44+/CD24+亚群的侵袭能力。我们的结果显示,乳腺癌组织中CCL5和CCR5的表达高于其相应正常组织,且TNM分期较高的乳腺癌组织中CCL5 mRNA含量更多。此外,MCF-7细胞中CD44+/CD24-亚群的CCR5表达及侵袭能力高于CD44+/CD24+亚群。而且,rhCCL5处理增加了CD44+/CD24-细胞的比例及MCF-7细胞的增殖。rhCCL5诱导增加了CD44+/CD24-和CD44+/CD24+细胞的侵袭能力,而CCR5单克隆抗体可部分拮抗这种作用。总体而言,我们的数据表明CCL5增加了CD44+/CD24-亚群的比例,并诱导MCF-7细胞侵袭和增殖,且乳腺癌组织中CCL5和CCR5的表达与乳腺癌进展呈正相关。